Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist tirzepat ...

A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...

Trulicity is another type of GLP-1 receptor agonist that is effective for reducing blood sugar levels and heart disease risk in people with diabetes. Like Ozempic, it’s an injectable medication ...

The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight loss and obesity drugs. Read more here.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...